Download biomedica product list
Custom Service Measurements for ELISA-Luminex-microRNA
Make Testing Easy
We at Biomedica offer tailored analytical testing services for ELISA Kits, Luminex Assays, and microRNA Analysis.
Custom Service Measurements for ELISA-Luminex-microRNA
Highlights:
-Professional: all analytics are carried out by experts
-Quality: we pursue excellence in quality
-Flexibility: tailored solutions according to your needs
-Efficient: save your time and budget – fast turnaround time
Learn more about the Biomedica Service Measurements here
Our measurement services include:
ELISA Assay Kits
We offer services for our proprietary Biomedica ELISA kits (see product list) as well as for ELISA Assays from other providers.
Luminex Technology Multiplex Assays
We utilize Luminex xMAP® (multiple analyte profiling) technology-based immunoassays, enabling the simultaneous detection and quantification of multiple biomarkers.
For more information please see our workflow chart or reach out to us directly to discuss how we can support your specific research project
NEXT-GENERATION SEQUENCING & RT-qPCR MICRORNA SERVICES
We provide a comprehensive range of high-quality RNA services, including RNA extraction, next-generation sequencing (NGS), RT-qPCR, and custom analysis of microRNA signatures, all performed by our experienced laboratory staff. Our services include:
- RNA extraction from biofluids (serum, plasma, extracellular vesicles), cells, and tissues (quality control of total RNA utilizes Bioanalyzer chips)
- Next-generation sequencing (NGS)
- RT-qPCR
- Cell-type specific microRNA/mRNA analysis in complex tissues, along with custom analysis of microRNA signatures
For more details about our microRNA services, please visit our website and contact us directly.
Literature
Circulating Micro-RNAs in Patients with Hypophosphatasia Results of the first micro-RNA analysis in HPP. Haschka J, Messner Z, Feurstein J, Hadzimuratovic B, Zwerina J, Diendorfer AB, Pultar M, Hackl M, Kuzma M, Payer J, Resch H, Kocijan R.J Clin Endocrinol Metab. 2025 Feb 11:dgaf080. doi: 10.1210/clinem/dgaf080. Epub ahead of print. PMID: 39930630.
Abstract
Introduction: Adult hypophosphatasia (HPP) patients present with diffuse heterogenous symptoms often mimicking rheumatological diseases or osteoporosis and therefore accompanied by delayed diagnosis. The aim of this study was to identify circulating miRNAs in adult HPP patients and to identify potential associations with clinical patients’ characteristics.
Methods: We utilized untargeted miRNA biomarker discovery by small RNA-sequencing to investigate cell-free miRNA profiles in 24 adult HPP patients (pathogenic variant of the ALPL gene, HPP-related clinical symptoms and repeatedly low ALP) and 24 healthy controls (CTRL).
Results: Patients and CTRL were comparable in age (47.9±14.2 vs. 45.9±8.8y, p=0.980) and sex (55.5% vs. 47.8% females, p=1.000). In total, 91% of patients reported musculoskeletal pain, 41% diffuse neurological symptoms and 64% history of fractures. In total, 84 miRNAs were significantly differently expressed between HPP and CTRL in next generation sequencing (NGS) analysis(p<0.05). Of these, 14 miRNAs were selected (selection criteria: p<0.05, tissue specificity index >0.7, log2 FC >+0.8 or < -0.8) for validation using RT-qPCR, which verified 6 of 14 selected miRNAs (p<0.05; miR-122-3p, miR-140-5p, miR-143-3p, miR-155-5p, miR-451a, miR-92a-3p). Target prediction and enrichment analysis identified associations with the musculoskeletal system and the central nervous system. In total, 37 miRNAs correlated with ALP levels, but only three miRNAs with PLP (pyridoxal-5′-phosphate).
Conclusions: These findings highlight a profound involvement of multiple organ systems and the potential of miRNAs as biomarkers for the effect of HPP on various systems.